| Name | Title | Contact Details |
|---|
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
KeySource Medical, Inc. (KMI) has been supplying the generic pharmaceutical needs of retail pharmacies across the United States since 1996. Our sales force is focused on serving the interests of our customers, emphasizing the highest level of service, integrity and value. As a trusted wholesale distributor of generic pharmaceuticals, we take our responsibility to safeguard the integrity of the pharmaceutical supply chain seriously, securing it against counterfeit or adulterated products. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America`s largest pharmaceutical distributors KMI has been recognized by “INC. Magazine” as one of America`s fastest growing, privately-held companies, placing #162 on the “INC. 500” list in 2006. In 2009, KMI was a finalist and category winner in the “Fast 55” competition sponsored by the Cincinnati Business Courier. KeySource Medical is committed to serving the community through the Dennis J. Engel Giving Program. We help make it possible to serve the uninsured and those in need with prescriptions at no cost through The St. Vincent de Paul Charitable Pharmacy.
KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Curve™ Spine Frame The KYRA Curve has a class-...